

## **FOREIGN INVESTMENT REVIEW BOARD APPROVAL OF UNDERWRITING OF \$6.5M RIGHT ISSUE**

**June 17 2020. Melbourne, Australia.** Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, wishes to update investors on the application submitted to the Foreign Investment Review Board (**FIRB**) by Mr Whitney George (Underwriter) to fully underwrite the renounceable rights issue (**Rights Issue**).

Mr George has advised the company that he has now received approval from the Foreign Investment Review Board (**FIRB**) to act as underwriter of the \$6.5m rights issue. The company can advise investors that the rights issue will proceed in line with the previously communicated timeline. As announced on 3 June 2020, the closing date for acceptance is 5pm (AEST) Friday 19 June 2020.

### **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne based ASX listed airway technology company that has developed a simple and innovative nasal stent to improve air flow to the lungs and deliver therapeutic agents.

With its initial product Turbine, Rhinomed has established a leading position in sports performance enhancement, as testified by athletes including two-time Tour de France winner Chris Froome. With its variant called Mute, the company has also entered the sleep sector to tackle the global snoring market while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is developing applications for the delivery of medical cannabis and for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in nearly 20,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe

and Australia.